Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.

about

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.

Item

http://www.wikidata.org/entity/Q55329093

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Immunogenicity and safety of t ...... bo controlled phase III trial.

@en

Immunogenicity and safety of t ...... bo controlled phase III trial.

@nl

type

Item

label

Immunogenicity and safety of t ...... bo controlled phase III trial.

@en

Immunogenicity and safety of t ...... bo controlled phase III trial.

@nl

prefLabel

Immunogenicity and safety of t ...... bo controlled phase III trial.

@en

Immunogenicity and safety of t ...... bo controlled phase III trial.

@nl

P1476

Immunogenicity and safety of t ...... ebo controlled phase III trial

@en

P2093

Christian Kreusel

http://www.w3.org/2001/XMLSchema#string

Darja Schmidt

http://www.w3.org/2001/XMLSchema#string

Edgar Turner Overton

http://www.w3.org/2001/XMLSchema#string

Eva Wagner

http://www.w3.org/2001/XMLSchema#string

Heinz Weidenthaler

http://www.w3.org/2001/XMLSchema#string

Nathaly Samy

http://www.w3.org/2001/XMLSchema#string

Paul Chaplin

http://www.w3.org/2001/XMLSchema#string

Philip Young

http://www.w3.org/2001/XMLSchema#string

Siegfried Rösch

http://www.w3.org/2001/XMLSchema#string

Sonja De Carli

http://www.w3.org/2001/XMLSchema#string

P2860

Smallpox vaccines for biodefense: need and feasibility

Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review

Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.

Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel.

A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.

Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.

Smallpox vaccination and bioterrorism with pox viruses.

A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination.

Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study population

P304

e0195897

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0195897

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Katrin Nopora

P577

2018-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29652929

http://www.w3.org/2001/XMLSchema#string

P921

Baztanga

phase III clinical trial

P932

5898760

http://www.w3.org/2001/XMLSchema#string